Dr. Boro Dropulić will talk about non-malignant applications of CAR-T and the accessibility of cell and gene therapies
GAITHERSBURG, Md., April 28, 2022 /PRNewswire/ — Caring Cross, a 501(c)(3) nonprofit organization dedicated to accelerating the development of advanced medicines and enabling access to treatments for all patients, everywhere, announced that the co-founder and executive director, Boro DropulicPh.D., MBA, will speak and participate in two panels at the International Society for Cell and Gene Therapy (ISCT) 2022 Annual Meeting. The meeting will be held in person at San Francisco, California on May 4-7, 2022.
The details of the panels are as follows:
|
Panel 1 |
Non-malignant applications of CAR-T |
|
Date: |
May 5and2022 |
|
Weather: |
8:45 a.m. PT |
|
Panel 2 |
Are cell and gene therapies a first luxury in the world? |
|
Date: |
May 6and2022 |
|
Weather: |
3:30 p.m. PT |
|
Register: |
www.isctglobal.org/isct2022/home |
Dr Dropulić said: “We look forward to speaking up and contributing to the discussion on these important panels. We look forward to sharing an update on our duoCAR-T anti-HIV cell therapeutic candidate which aims to eliminate HIV-infected cells and protect CD4 T cells from HIV infection in people living with HIV. HIV. We also look forward to sharing our insights on reducing the cost of personalized gene-edited autologous cell therapies by integrating point-of-care manufacturing into healthcare infrastructures. Our goal is to help overcome the socio-economic and geographic limitations to affordability and accessibility of cell and gene therapies.
About the Benevolent Cross
Caring Cross is a 501(c)(3) nonprofit organization dedicated to accelerating the development of advanced medicines and ensuring access to treatments for all patients, everywhere. To carry out its mission, Caring Cross engages a growing community of healthcare professionals, scientists, engineers, community advocates, donors, investors and business leaders to support the development of technologies and candidate drugs and technologies. Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability, and applicability of CAR-T technology and stem cell gene therapy. These opportunities include developing and implementing affordable solutions for manufacturing CAR-T cells, promoting a decentralized point-of-care cell manufacturing model, and developing its first therapeutic candidate, a cell therapy DuoCAR-T HIV drug designed to suppress HIV. replication and elimination of HIV-expressing cells in people living with HIV. Stem cell gene therapy for sickle cell disease and beta-thalassemia is also being developed. For more information about Caring Cross, visit https://caringcross.org/.
CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
862-213-1398
dboateng@tiberend.com
Media
Rosalyn Christian
862-353-9266
rchristian@tiberend.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/caring-cross-to-speak-and-participate-at-two-panels-at-the-international-society-for -cell –gene-therapy-annual-meeting-2022-301535485.html
SOURCE Benevolent Cross
